Does disease-targeted therapy improve survival in patients with Eisenmenger syndrome?
Disease-targeted therapy is associated with improved survival in Eisenmenger syndrome patients, who otherwise face alarmingly high 10-year mortality rates of 60-70%.
This study illustrates the alarmingly poor survival prospects of Eisenmenger patients by community-based data even in the current era with advanced DTT and in a country with a wealthy health system. Treatment naive ES patients had especially high mortality rates approaching 60-70% at 10 years of follow-up. Treatment with DTT was associated with better survival.
Diller et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: